In short
Clinical trials are investigating HUMAN IGG4 KAPPA MONOCLONAL ANTIBODY AGAINST PLATELET-DERIVED GROWTH FACTOR SUBUNIT B in adults with pulmonary arterial hypertension. These studies aim to evaluate its effect on pulmonary vascular resistance and other research outcomes, with a focus on safety and possible benefit in this patient group.
Key points
- Clinical trials are studying HUMAN IGG4 KAPPA MONOCLONAL ANTIBODY AGAINST PLATELET-DERIVED GROWTH FACTOR SUBUNIT B in adults with pulmonary arterial hypertension, also called PAH. The trial is a Phase 2 interventional study with 99 planned participants. The main goal is to measure change from baseline in pulmonary vascular resistance, or PVR. The study also includes a placebo comparison. Overall, the trial is focused on whether the treatment may help people with PAH and how its effects can be measured in this group.
Trial overview
The available trial data describe a Phase 2 study of HUMAN IGG4 KAPPA MONOCLONAL ANTIBODY AGAINST PLATELET-DERIVED GROWTH FACTOR SUBUNIT B in adults with pulmonary arterial hypertension (PAH). The brief study summary says the goal is to evaluate the effect of the study treatment on pulmonary vascular resistance (PVR).
Who is being studied
This trial is for adult participants with PAH. The source data do not give more detailed inclusion or exclusion rules, so the full list of who can join is not available here.
Trial design and treatment groups
The study is listed as an interventional trial, which means researchers assign a treatment and then measure the results. The intervention list includes HUMAN IGG4 KAPPA MONOCLONAL ANTIBODY AGAINST PLATELET-DERIVED GROWTH FACTOR SUBUNIT B and a placebo group, which helps compare outcomes fairly. The intervention routes shown in the source are intravenous, subcutaneous, and intramuscular, but the data do not explain how these are used in the full study plan.
What the study measures
The main outcome is the change from baseline in pulmonary vascular resistance (PVR). Baseline means the starting measurement before treatment begins, and PVR is a measure of how hard it is for blood to flow through the lung blood vessels. In simple terms, the study is checking whether the treatment changes the pressure or resistance in the lung circulation compared with the starting point.
Trial status and size
The trial status is listed as Authorised. The planned enrollment is 99 participants, which means up to 99 people are expected to be included in the study.
What this means for patients
For people living with PAH, this study is part of early-to-mid stage clinical research looking for signs that HUMAN IGG4 KAPPA MONOCLONAL ANTIBODY AGAINST PLATELET-DERIVED GROWTH FACTOR SUBUNIT B may affect lung blood flow measurements. Because the trial is Phase 2, it is mainly focused on learning more about possible benefit while continuing to gather research information. The source data do not report final results, so the trial should be seen as an ongoing or planned research effort rather than a proven treatment answer.